Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway.

Cancer Chemother Pharmacol · 2017 · PMC5225176 · PMID 27913881

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

Similarly, multivariate analysis demonstrated high AUC 0–24h of 5-FU was borderline significant predictor of prolonged TTF (supplementary Table S6).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.